Get started
Author

Bin Zou

Observed institution: Johnson & Johnson (United States)
OpenAlex ID: A5135168141
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis
2026 · Maria T. Abreu, Britta Siegmund, et al. · New England Journal of Medicine
O60 Icotrokinra, a targeted oral peptide that blocks IL-23 receptor activation, in moderate-to-severe ulcerative colitis: week 12 results from ANTHEM-UC
2026 · Jimmy Limdi, Maria T Abreu, et al.
PDF
487 Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastrointestinal Endoscopy
487 Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastroenterology
Works count: 4
Citation count:
H-index:
I10-index:
Year
Topic
Type